太疯狂！突然暴涨超115%！上半年营收为0→

Core Viewpoint - The stock of the biotech company,药捷安康, surged significantly after announcing the initiation of a Phase II clinical trial for its core product, TT-00420, aimed at treating HR+/HER2- recurrent or metastatic breast cancer, which received implied approval from the Chinese National Medical Products Administration [3][6]. Group 1: Stock Performance - On September 15,药捷安康's stock opened strong and peaked at a 124.10% increase, closing at 415.00 HKD per share, marking a 115.58% rise for the day [1]. - Following the announcement of the clinical trial,药捷安康's stock price increased for four consecutive trading days, accumulating a total rise of nearly 500% [6]. - The overall 18A biotech sector, influenced by药捷安康, saw a rise of 15.63%, leading among various concept sectors [6]. Group 2: Clinical Trial Details - The Phase II clinical trial for TT-00420, in combination with Fulvestrant, is an open-label, multi-center study designed to evaluate the safety, efficacy, and pharmacokinetics of the treatment [3]. - The trial is expected to receive implied approval by September 10, 2025, from the Chinese National Medical Products Administration [3]. Group 3: Financial Performance - Currently,药捷安康 has no commercialized products, reporting zero revenue and a loss of 123 million CNY in the first half of the year [11].